Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., ...

KALA BIO, Inc. announces $10.75 million private placement to advance clinical development of KPI-012 for severe eye diseases. KALA Bio, Inc., a clinical-stage biopharmaceutical company focused on ...

Key Insights The projected fair value for Climb Bio is US$9.09 based on 2 Stage Free Cash Flow to Equity Climb ...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Gritstone bio, Inc. (NASDAQ: ...

Q32 Bio Inc ((QTTB)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...